menu
    • menu
    [{"orgOrder":0,"company":"Roca Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RCT002","moa":"CXCR2\/DRAK1","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Roca Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Roca Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Roca Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Roca Therapeutics","sponsor":"3B Future Health Fund II","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"RCT001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Roca Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roca Therapeutics \/ 3B Future Health Fund II","highestDevelopmentStatusID":"5","companyTruncated":"Roca Therapeutics \/ 3B Future Health Fund II"}]

    Find Clinical Drug Pipeline Developments & Deals by Roca Therapeutics

    Menu

    Roca Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Roca Therapeutics

                            France arrow
                            Global ChemShow
                            Not Confirmed

                            Roca Therapeutics

                            France arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RCT002

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EMA Grants Orphan Status To Roca In Radiation Maculopathy

                            Details : RCT002 is a topically administered small-molecule drug candidate designed to target CXCR2 and DRAK1, bein investigated for radiation maculopathy.

                            Product Name : RCT002

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 26, 2025

                            Lead Product(s) : RCT002

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Roca Therapeutics

                            France arrow
                            Global ChemShow
                            Not Confirmed

                            Roca Therapeutics

                            France arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RCT001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : 3B Future Health Fund II

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Roca Therapeutics Completes Seed Funding Round

                            Details : Company will use funds to develop its lead candidate RCT001 (Metastatic Uveal Melanoma) until IND/CTA readiness in 2023, and to expand portfolio of assets with the nomination of a second clinical candidate against Neovascular Glaucoma associated to Uveal...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 22, 2022

                            Lead Product(s) : RCT001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : 3B Future Health Fund II

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth